A retrospective study on the use of VEGFR inhibitor regorafenib combined with PD-1 inhibitors in MSS/pMMR CRC patients revealed that while no objective responses were observed, the disease control rate was 78.3% (96). This evidence concerns the gene KDR and colorectal carcinoma.